Ovarian Cancer Dx Field Heats Up As New Protein Biomarker Test from UPMC Shows Best Results Yet | GenomeWeb

Researchers at the University of Pittsburgh Medical Center have developed a new ovarian cancer screening test that they claim has a specificity of 98 percent and a sensitivity of about 93 percent, giving it a higher diagnostic power than any other published ovarian cancer assay to date.

UPMC researchers led by Anna Lokshin, an assistant professor of medicine and pathology, used a biomarker panel comprising 20 proteins to test 150 ovarian cancer patients and 150 controls.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In PNAS this week: miR-515 levels higher in women with preeclampsia, horizontal gene transfer in parasitic plants, and more.

A cancer researcher retracts 19 articles from one journal for image manipulation, according to Retraction Watch.

Precision medicine has to consider context in addition to genetic mutations in cancer treatment, Medscape reports.

Genomics may help the Cavendish banana from succumbing to fungal infections, a trio of researchers writes at the Conversation.